In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.
After I graduated with a master’s degree in European Law from the
University of Tours, I decided to study journalism at the All Media
Journalism Institute of Lille. During this time, I discovered the healthcare
innovation ecosystem and enjoyed writing about it for Eurasanté, a French
healthcare cluster. I am interested in different subjects other than
healthcare and biotechnology: cinema, sports, photography… Journalism
had always been at the back of my mind, and I am delighted to write for
Labiotech as a junior reporter. When I am not working you might find me on the tennis court or picking up the next piece of furniture I will renovate.